Stock Analysis

TianYu Bio-Technology Second Quarter 2024 Earnings: CN¥0.01 loss per share (vs CN¥0.23 loss in 2Q 2023)

SHSE:603717

TianYu Bio-Technology (SHSE:603717) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥212.2m (down 13% from 2Q 2023).
  • Net loss: CN¥2.80m (loss narrowed by 94% from 2Q 2023).
  • CN¥0.01 loss per share (improved from CN¥0.23 loss in 2Q 2023).
SHSE:603717 Earnings and Revenue History September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

TianYu Bio-Technology shares are up 2.8% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with TianYu Bio-Technology, and understanding it should be part of your investment process.

Valuation is complex, but we're here to simplify it.

Discover if TianYu Bio-Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.